Lexicon Pharmaceuticals | LXRX - Spese Di Vendita E Di Amministrazione





Spese Di Vendita E Di Amministrazione Cambiamento Data
Abbott USD 3.13B 125M 2025-12
Acadia Pharmaceuticals USD 146.73M 21.82M 2025-12
Agios Pharmaceuticals USD 42.97M 1.7M 2025-12
Akebia Therapeutics USD 23.53M 3.19M 2025-12
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
AstraZeneca USD 4.61B 4.46B 2025-12
BioMarin Pharmaceutical USD 322.21M 98.79M 2025-12
Coherus Biosciences USD 15M 6.26M 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Esperion Therapeutics USD 39.42M 456K 2025-12
Halozyme Therapeutics USD 64.64M 27.11M 2025-12
Illumina USD 283M 27M 2025-12
Insmed USD 212.48M 26.11M 2025-12
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
J&J USD 6.75B 831M 2025-12
Lexicon Pharmaceuticals USD 3.98M 195K 2025-12
MacroGenics USD 7.94M 1.96M 2025-12
MannKind USD 29.09M 2.53M 2025-09
Merck USD 2.85B 215M 2025-12
Moderna USD 308M 40M 2025-12
Novartis USD 3.44B 128M 2025-12
PTC Therapeutics USD 87.2M 3.15M 2025-12
Puma Biotechnology USD 16.82M 8.15M 2024-09
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
Thermo Fisher Scientific USD 1.98B 182M 2025-12
Ultragenyx Pharmaceutical USD 89M 2.38M 2025-12
United Therapeutics USD 190.6M 38.6M 2025-12
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12